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Increased Rho Kinase Activity
in a Taiwanese Population With Metabolic Syndrome
Ping-Yen Liu, MD, PHD,*†‡ Jyh-Hong Chen, MD, PHD, FACC,*† Li-Jen Lin, MD,*†
James K. Liao, MD, FACC‡
Tainan, Taiwan; and Boston, Massachusetts
Objectives We sought to determine whether Rho kinase (ROCK) activity is increased in a Taiwanese population with meta-
bolic syndrome (MetS).
Background Recent studies suggest that ROCK may be involved in the pathogenesis of MetS, but clinical studies linking
ROCK with MetS are lacking.
Methods We studied 40 Taiwanese subjects (60% men, mean age 55.5  5.6 years) who were diagnosed with MetS with
National Cholesterol Educational Program Adult Treatment Panel III criteria and 40 age- and gender-matched
control subjects. Subject demographics were recorded, and blood samples were obtained.
Results Compared with control subjects, ROCK activity, as determined by phosphorylation of myosin binding subunit
(MBS) in leukocytes, was greater in MetS subjects (mean phospho-MBS/MBS ratio 0.46 vs. 0.35, p  0.002).
A cutoff value for ROCK activity of 0.39 predicted the presence of MetS with specificity and sensitivity rates of
70%. Plasma high-sensitivity C-reactive protein was greater (5.5 mg/l, 95% confidence interval [CI] 3.1 to 7.2
mg/l vs. 2.8 mg/l, 95% CI 1.1 to 3.9 mg/l, p  0.01) and adiponectin was lower (4.9 g/ml, 95% CI 3.2 to 6.1
g/ml vs. 5.9 g/ml, 95% CI 4.2 to 7.5 g/ml, p  0.01) in MetS subjects compared with control subjects, but
plasma levels of interleukin-6 and tumor necrosis factor-alpha were not different (p  0.05 for both). Body
mass index, waist circumference, fasting glucose, high-sensitivity C-reactive protein, and triglyceride levels
were associated with increased levels of ROCK activity. The risk of increased ROCK activity increased with
the number of MetS components (p for trend 0.001).
Conclusions Rho kinase activity is increased in Taiwanese subjects with MetS and is associated with each component of
MetS and markers of inflammation. These findings suggest that ROCK activity may be a novel serological
marker of MetS. (J Am Coll Cardiol 2007;49:1619–24) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.043E
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aetabolic syndrome (MetS) is a cluster of atherosclerotic
ardiovascular disease risk factors and is closely associated
ith insulin resistance and obesity (1,2). The precise diag-
osis of MetS, however, is still somewhat controversial, and
o serological markers are available for its detection. Nev-
rtheless, according to the criteria of National Cholesterol
ducational Program Adult Treatment Panel (ATP)-III
3), the prevalence of MetS in U.S. adults who are older
han 20 years of age is approximately 24% (4). Metabolic
yndrome is a growing problem worldwide, particularly in
he Asian population (5). The World Health Organization
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006, accepted December 19, 2006.xpert Consultation recommended a lower cut-off point for
bserved risk in Asian populations than that for non-Asian
opulations, varying from 22 to 25 kg/m2 (6). Some studies
n migrants from Asian countries to Western countries also
ndicated that Asian populations might be more susceptible
o the Western diet and lifestyle than white ones in
eveloping the MetS (7,8). Patients with MetS have twice
he incidence of developing new-onset diabetes compared
ith those without MetS (9). Metabolic syndrome, there-
ore, is associated with increasing risk of developing diabetes
nd cardiovascular disease.
Several inflammatory mediators and adipocytokines, in-
luding tumor necrosis factor (TNF)-alpha (10), interleukin
IL)-6 (11), high-sensitivity C-reactive protein (hs-CRP)
12,13), and adiponectin (14) are associated with the develop-
ent of insulin resistance and MetS (15,16). Despite these
ssociations, the pathogenesis of MetS remains unknown.
e recently reported that Rho kinase (ROCK) mediates
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activator inhibitor-1 under hy-
perglycemic conditions (17).
Furthermore, ROCK is up-
regulated under inflammatory
conditions (18) and may be in-
volved in adipocyte differentia-
tion (19). Thus, growing evi-
dence suggest that ROCK may
contribute to the pathogenesis of
MetS. However, clinical studies
are lacking, which definitively
link ROCK activity with MetS.
Rho kinase is a serine/threonine
kinase that mediates the down-
stream signaling of the small
guanosine triphosphate–binding
protein, Rho, on the actin cy-
toskeleton (20). ROCK consists
of 2 isoforms, ROCK1 and
ROCK2. In mostly animal mod-
els, the inhibition of ROCK
meliorates many cardiovascular conditions, including hy-
ertension (21), atherosclerosis (22), myocardial fibrosis
23), and stroke (24). Furthermore, ROCK also could
egulate insulin signaling and glucose metabolism through
irect phosphorylation of the insulin receptor substrate
IRS)-1 (25). Thus, it is likely that ROCK plays an
mportant role in the pathogenesis of MetS and diabetes.
owever, evidence is lacking showing that ROCK activity
s increased in human subjects with MetS. In the current
tudy, we measured ROCK activity in Taiwanese popula-
ion with MetS and determined whether ROCK activity is
n independent marker of MetS and whether it correlates
ith other components and risk markers of MetS.
aterials and Methods
tudy subjects. We prospectively enrolled 40 consecutive
aiwanese patients (60% men, ages 35 to 62 years), who
ere diagnosed with MetS with ATP-III criteria, from an
utpatient clinic at the National Cheng Kung University
edical Center from 2005 to 2006. Patients who had a
istory of percutaneous coronary intervention within 6
onths or coronary artery bypass surgery within 1 year were
xcluded. Other exclusion criteria included patients who
ad heart failure, cardiomyopathy, or valvular heart diseases.
ecause statins could affect ROCK activity through modu-
ation of Rho (26), patients taking statins before enrollment
lso were excluded. A volunteer control group consisting of
ge- and gender-matched healthy subjects (n  40, 60%
en), with a mean age of 53.8  6.6 years, also was
nrolled. These control subjects showed no clinical or
lectrocardiographic evidence of ischemia or cerebrovascular
isease. All subjects provided their informed consent. The
Abbreviations
and Acronyms
BMI  body mass index
HBSS  Hanks’ balanced
salt solution
HDL-C  high-density
lipoprotein cholesterol
hs-CRP  high-sensitivity
C-reactive protein
IL  interleukin
IRS  insulin receptor
substrate
MBS  myosin binding
subunit
MetS  metabolic
syndrome
ROCK  Rho kinase
TG  triglycerides
TNF  tumor necrosis
factortudy protocol was approved by the Human Research Eubjects review committee of the National Cheng Kung
niversity Medical Center.
efinition of MetS. We used ATP-III criteria for MetS
3), which require 3 or more of the following components:
) obesity as defined by waist circumference 102 cm (40
nches) in men and 88 cm (35 inches) in women; 2) a low
evel of high-density lipoprotein cholesterol (HDL-C),
efined as HDL-C 40 mg/dl in men and 50 mg/dl in
omen; 3) high triglycerides (TG), defined as TG 150
g/dl; 4) high level of glucose, defined as fasting glucose
110 mg/dl; and 5) increased blood pressure, defined as
lood pressure 130/85 mm Hg.
iochemical analysis. Venous blood samples were drawn
rom each subject after 8 h or overnight fasting. The
amples were stored at 80°C until biochemical assay by
linded investigators. Triglycerides were determined enzy-
atically. High-density lipoprotein cholesterol was mea-
ured by the phosphotungstate method. Glucose was enzy-
atically determined by the hexokinase method. Tumor
ecrosis factor-alpha was measured by enzyme immunoas-
ay with a minimum detectable level of 6 pg/ml (Dainippon
harmaceutical Co., Ltd., Osaka, Japan). High-sensitivity
L-6 was also measured by enzyme immunoassay (Dainip-
on Pharmaceutical Co., Ltd.). High-sensitivity CRP was
easured by latex nephelometry (BNII, Dade Behring Co.,
td., Milton Keynes, Buckinghamshire, United Kingdom).
diponectin concentrations were determined by enzyme-
inked immunosorbent assay (Otsuka Pharmaceutical Co.,
td., Rockville, Maryland). Interassay coefficients of varia-
ion of each variable were as follows: TNF-alpha, 9.6%;
L-6, 7.5%; hs-CRP, 4.0%; adiponectin, 8.6%.
eukocyte isolation. Twenty milliliters of blood sample
as mixed with Hanks’ balanced salt solution (HBSS) in a
0-ml citrate-containing tube. Ten milliliters of Histopaque
Histopaque-1077, Sigma Chemical Co., St. Louis, Mis-
ouri) were layered with 25 ml of diluted blood in 2 tubes
nd centrifuged at room temperature for 30 min at 350 g.
he supernatant containing the leukocytes was aspirated,
ixed with HBSS and diluted with 2% dextran (1:1 ratio),
nd kept rest at room temperature for 30 min. The top layer
s then aspirated, mixed with HBSS, and centrifuged at
oom temperature for 5 min at 350 g. The supernatant was
iscarded, and the pellet containing the leukocytes was
esuspended in 3 ml of cold phosphate-buffered saline. After
wirling the tubes for 30 s, HBSS was added to stop the
ysis. After centrifugation, the supernatant was discarded,
nd the pellet was resuspended in 5 ml of M199.
After determining cell yield and viability by using the
rypan blue exclusion test (usually 4 to 80  106 viable cells
ith a viability of more than 95%), we diluted the suspen-
ion with HBSS to achieve 5  106 cells/ml. Then, 400 l
f the leukocyte suspension was transferred to 4 sterile 1.5-ml
ubes. We added 100 l of fixative solution (50% trichloro-
cetic acid [Sigma]), 50 mmol/l dichlorodiphenyltrichloro-
thane (Sigma), and protease inhibitors (Calbiochem,
MD Biosciences, Inc., Darmstadt, Germany) to each
t
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April 17, 2007:1619–24 ROCK and Metabolic Syndromeube. After vortexing and centrifuging the samples at 4°C
or 5 min at 11,000 g, we removed the supernatant, added
BSS, and centrifuged the samples again at 4°C for 1 min
t 11,000 g. Finally, we removed the supernatant with a
icropipette. The leukocyte pellets were stored at 80° C
ntil use.
ssay for ROCK expression and activity. After centrifu-
ation, pellets were dissolved in 10 l of 1 mol/l Tris and
ixed with 100 l of extraction buffer (8 mol/l urea,
% sodium dodecyl sulfate, 5% sucrose, and 5%
-mercaptoethanol, 0.02% BPB dye). Equal amounts of cell
xtracts were subjected to 7.5% sodium dodecyl sulfate poly-
crylamide gel electrophoresis and transferred onto polyvinyli-
ene fluoride membrane (Immobilon-P, Millipore, Billerica,
assachusetts). NIH 3T3 cell lysates were used as a positive
ontrol and to standardize the results of Western blot
nalyses from several membranes. The membranes were
ncubated with rabbit anti-phospho-specific Thr853-myosin
inding subunit (MBS) polyclonal antibody (Biosource-
nvitrogen, Carlsbad, California) (17), rabbit anti-MBS
olyclonal antibody (Covance, Princeton, New Jersey), anti-
OCK2 monoclonal antibody, anti-ROCK1 monoclonal
ntibody (BD Biosciences, San Jose, California), or anti-
ctin monoclonal antibody (Sigma). Bands were visualized
ith the use of the ECL detection kit (Amersham Bio-
ciences, a division of GE Healthcare, Piscataway, New
ersey). Rho kinase activity was expressed as the ratio of
hosphorylation levels of myosin binding subunit (pMBS)
n each sample per pMBS in each positive control divided by
BS in each sample per MBS in each positive control.
tatistical analysis. All statistical analyses were conducted
ith the SPSS statistical package for Windows version 13.0
SPSS Inc., Chicago, Illinois). The frequencies between
etS and the controls were compared with chi-square
nalysis. Independent-samples t test was used for compar-
son of mean values of parametric continuous variables
expressed as mean  SD) between MetS and control
roups. Because of asymmetric distribution, values for
NF-alpha, IL-6, hs-CRP, and adiponectin were analyzed
y nonparametric methods and shown as the geometric
eans with 95% confidence intervals for those means. For
onparametric analysis, we used Mann-Whitney U test to
valuate the difference of levels between groups. Receiver-
perating characteristic analysis was performed to determine
he best cutoff value of ROCK activity to differentiate MetS
nd the control subjects. Because smoking status was found
o strongly influence ROCK activity (27) and ROCK
ctivity itself was not normally distributed, we used partial
orrelation coefficients adjusted for smoking status to com-
ute the association between inflammation-related markers
nd levels of ROCK activity. The odds ratios by number of
he MetS components for elevated ROCK activity were also
alculated. All reported p values were 2-sided, and a p value
f 0.05 was considered statistically significant. esults
he prevalence of cardiovascular risk factors, including
ypertension, fasting glucose levels, lipid profiles, smoking,
ody mass index (BMI), and waist circumference, are shown
or control and MetS subjects (Table 1). Compared with the
ontrol group, the average age, gender, medications for
ypertension and glucose control, and percentage of smok-
rs in the MetS group were similar. Blood pressure, fasting
lucose, low-density lipoprotein cholesterol, TG levels,
MI, and waist circumference were all greater among MetS
ubjects, and HDL-C levels were lower among MetS
ubjects.
The protein levels of ROCK1 and ROCK2 were similar
n control and MetS subjects (Figs. 1A and 1B). However,
ompared with control subjects, MetS subjects had greater
OCK activities, as measured by pMBS/MBS (Figs. 1C
nd 1D). Among the inflammatory markers measured,
lasma hs-CRP levels were greater in MetS subjects com-
ared with those of control subjects, but not IL-6 or
NF-alpha (Table 2). Adiponectin levels were lower in
etS subjects. The cutoff value for ROCK activity that
redicted the presence of MetS was 0.39 by receiver-
perating characteristic analysis (area under curve  0.76 
.07, range 0.63 to 0.89, p 0.001) (Fig. 2). The sensitivity
nd specificity rates for this ratio in detecting MetS in our
ohort were 70% and 70%, respectively.
To determine whether ROCK activity is a novel risk
arker for MetS and whether it correlates with components
f MetS, we performed an association analysis to determine
he correlation coefficient of ROCK activity with compo-
ents of MetS (Table 3). Among the associated factors,
MI, waist circumference, fasting glucose, hs-CRP, and
G levels were all positively associated with increased levels
f ROCK activity. In contrast, adiponectin and HDL-C
evels were negatively associated with ROCK activity. After
djusting for age and smoking, those subjects with a greater
umber of MetS components (3) had higher odds ratios
or elevated ROCK activity when compared with those with
linical Manifestations ofetabolic Syndrome and Control Subjects
Table 1 Clinical Manifestations ofMetabolic Syndrome and Control Subjects
Controls (n  40) MetS (n  40) p Value
Age (yrs) 59.6 6.5 60.1 6.7 0.813
Gender (male) 24 (60%) 24 (60%) 0.815
Hypertension 8 (20%) 18 (45%) 0.004
BMI (kg/m2) 24.1 2.2 33.4 1.5 0.001
Fasting glucose (mg/dl) 93.5 5.9 120.8 5.9 0.001
LDL-C (mg/dl) 122 8 131 11 0.01
TG (mg/dl) 147 18 159 22 0.02
HDL-C (mg/dl) 49 6 34 5 0.002
Waist circumference (cm) 84.3 7.2 104.3 8.9 0.001
alues are expressed as mean SD or n (%).
BMI  body mass index; HDL-C  high-density lipoprotein cholesterol; LDL-C  low-density
ipoprotein cholesterol; MetS  metabolic syndrome; TG  triglycerides.3 components. These findings suggest that elevated
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ROCK and Metabolic Syndrome April 17, 2007:1619–24OCK activity requires the presence of several risk compo-
ents that are associated with MetS (Table 4).
iscussion
e have shown that ROCK activity is greater among
aiwanese subjects with MetS. Increased levels of ROCK
ctivity (pMBS/MBS ratio 0.39), independently predict
he diagnosis of MetS. In addition, higher ROCK activity
as associated with several components of MetS, such as
reater BMI and waist circumference, and correlated with
reater hs-CRP and lower adiponectin levels. These find-
Figure 1 ROCK Activity Is Greater Among Asian Subjects With
(A) Baseline protein expression of Rho kinase (ROCK)1 by immunoblotting method
lation levels of MBS (pMBS) and total MBS (tMBS) were determined by immunoblo
drome (MetS) patients and controls. Three repeated experiments were performed
aseline Inflammatory Markers ofetabolic Syndrome Subjects and Control Subjects
Table 2 Baseline Inflammatory Markers ofMetabolic Syndrome Subjects and Control Subjects
Control (n  40) MetS (n  40) p Value
hs-CRP (mg/l) 2.8 (1.1–3.9) 5.5 (3.1–7.2) 0.01
IL-6 (pg/ml) 1.7 (0.9–1.9) 1.8 (1.1–2.1) 0.77
TNF- (pg/ml) 12.0 (10.1–14.1) 12.8 (9.9–15.2) 0.91
Adiponectin (g/ml) 5.9 (4.2–7.5) 4.9 (3.2–6.1) 0.01
alues are expressed as geometric means with corresponding 95% confidence intervals (inM
arentheses).
hs-CRP  high-sensitivity C-reactive protein; IL  interleukin; TNF  tumor necrosis factor.ngs indicate that ROCK activity is a novel risk marker for
etS and suggest that ROCK may be involved in the
evelopment and progression of MetS.
Although the precise mechanism by which ROCK activ-
ty is increased among MetS subjects is not known, several
ossible mechanisms could explain the observed findings.
or example, increased ROCK activity is associated with
ypertension and phosphorylation of IRS-1 by ROCK,
hich prevents insulin signaling and glucose transporter-4
ranslocation, could lead to altered glucose metabolism
19,26). Interestingly, inhibition of ROCK ameliorates
nsulin sensitivity in obese, but not lean, rats suggesting that
OCK activity is increased by obesity (28). Another pos-
ibility that links elevated ROCK activity with MetS is
nflammation. Several inflammatory molecules and adipo-
ytokines, including TNF-alpha, IL-6, and hs-CRP, have
een shown to be associated with insulin resistance and
etS (10–14). However, in the present cohort, higher
s-CRP, but not TNF-alpha or IL-6, was associated with
reater ROCK activity. Interestingly, some studies showed
hat hs-CRP, but not TNF-alpha or IL-6, is associated with
aseline protein expression of ROCK2 by immunoblotting method; (C) phosphory-
ethods; (D) ROCK activity, expressed as pMBS/MBS, between metabolic syn-
licate.MetS
; (B) b
tting m
in dupetS (14,29,30). Nevertheless, the lack of association
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April 17, 2007:1619–24 ROCK and Metabolic Syndromeetween ROCK and TNF-alpha or IL-6 might be due to
oth the wide range of distribution of TNF-alpha and IL-6
n our cohort and the small number of subjects in the
resent study.
Rho kinase activity was greater among MetS subjects,
hich may correlate with insulin resistance. In our study,
ost of our patients were obese with greater BMI and waist
ircumference values, 2 contributors to MetS and insulin
esistance. Insulin resistance acts as bridge between obesity
nd each component of MetS via different mechanisms,
ncluding altering lipid metabolism (19,25) and adipokine
ecretions (14). Indeed, weight loss can result in clinical
eaningful improvements in multiple metabolic parameters
nd blood pressure (31). Obesity itself can precipitate an
Figure 2 ROC Analysis to Determine
the Cutoff Value to Differentiate MetS
The best cutoff value for Rho kinase activity to differentiate the presence of
metabolic syndrome (MetS) was 0.39; both sensitivity and specificity rates
were 70%. The area under the curve  0.76  0.07, p  0.001. ROC 
receiver-operating characteristic.
artial Correlation Coefficient Adjusted for Smokingta us Between Clinical and Biochemicalamet rs With Rh Kinase Activity Amonge abolic Syndr me Subjects
Table 3
Partial Correlation Coefficient Adjusted for Smoking
Status Between Clinical and Biochemical
Parameters With Rho Kinase Activity Among
Metabolic Syndrome Subjects
Covariants Coefficient p Value (2-tail)
BMI 0.523 0.001
Fasting glucose 0.410 0.009
Waist circumference 0.412 0.009
Adiponectin 0.412 0.009
hs-CRP 0.359 0.023
HDL-C 0.352 0.026
TG 0.356 0.024
Age 0.157 0.333Rbbreviations as in Tables 1 and 2.nflammatory response and lead to free radical generation
32), thus further augmenting ROCK signaling. Indeed,
besity is one of the major components of MetS. Interest-
ngly, ROCKs are involved in adipocyte differentiation (19),
hich also may affect the pathogenesis of MetS. As men-
ioned previously, increased ROCK activity could lead to
he phosphorylation of IRS-1 and subsequently impaired
he glycogen synthase or glucose transportation in periph-
ral tissues, thereby increasing insulin resistance.
In our current study, despite increase in leukocyte ROCK
ctivity in MetS subjects, ROCK1 and ROCK2 expression
ere similar in control and MetS subjects. These findings
uggest that the activation of ROCK rather than induction
f ROCK expression is the underlying mechanism that is
ssociated with components of the metabolic syndrome.
ndeed, agents or conditions that increase ROCK activity
enerally do not affect ROCK expression because the
egulation of ROCKs occurs through their association with
ctivated Rho guanosine triphosphatase in response to
-protein–coupled receptors or growth factors. Thus, con-
itions associated with components of the metabolic syn-
rome, such as hypertension, smoking, and dyslipidemia,
re more likely to lead to the activation of the Rho/ROCK
athway rather than induction of ROCK expression. It
emains to be determined how components of MetS lead to
he activation of ROCK.
tudy limitations. Some limitations of this study should be
oted. First, the present case-control study did not allow for
nferring causality, which should be considered hypothesis
enerating and requires further confirmation by prospective
tudies and, if possible, therapeutic clinical trials. Second, all
ubjects in the present study were Taiwanese. Thus, the
resent results may not extrapolate to other ethnic groups.
evertheless, our finding showing that ROCK activity is an
mportant serological marker of MetS may help clarify the
iagnosis of MetS in future patient populations.
onclusions
ur results show that ROCK activity is elevated among
etS human subjects and associated with some inflamma-
ory markers. It remains to be determined whether increased
djusted Odds Ratios of Greater ROCKctivi y With the Number of M tS Components
Table 4 Adjusted Odds Ratios of Greater ROCKActivity With the Number of MetS Components
Number of MetS Components
Odds Ratio (95% CI) for Greater ROCK
Activity (phospho-MBS/MBS >0.39)*
0 1.0
1 1.15 (0.94–1.46)
2 1.29 (0.99–1.93)
3 1.89 (1.34–2.66)‡
4 2.70 (1.98–4.18)†
Trend 0.001
Risks are compared with subjects without any risk factor component of metabolic syndrome
MetS) and adjusted for age and smoking status. ‡p  0.01; †p  0.001.
CI  confidence interval; MBS  myosin binding subunit; ROCK  Rho kinase.OCK activity correlates with increase cardiovascular event
r
a
R
B
2
h
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
1624 Liu et al. JACC Vol. 49, No. 15, 2007
ROCK and Metabolic Syndrome April 17, 2007:1619–24ates in MetS and whether reduction of ROCK activity is
ssociated with therapeutic benefits in subjects with MetS.
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